Inhibiting S100B Restores p53 Levels in Primary Malignant Melanoma Cancer Cells*

Received for publication, May 14, 2004, and in revised form, June 2, 2004
Published, JBC Papers in Press, June 3, 2004, DOI 10.1074/jbc.M405419200

Jing Lin, Qingyuan Yang, Zhe Yan, Joseph Markowitz, Paul T. Wilder, France Carrier‡, and David J. Weber§

From the Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, Maryland 21201

S100 calcium-binding proteins such as S100B are elevated in primary malignant melanoma and are used as markers for this and numerous other cancers. Wild-type p53 protein levels are relatively low in these cancer cells (i.e. when compared with cells without S100B) but are elevated when RNA antisense to S100B is introduced. This result implicates S100B in the down-regulation of p53 and is consistent with the large decreases in p53 protein levels observed previously in transient co-transfections of p53 and S100B (Lin, J., Blake, M., Tang, C., Zimmer, D., Rustandi, R. R., Weber, D. J., and Carriere, F. (2001) J. Biol. Chem. 276, 35037–5041). Down-regulation of p53 in primary malignant melanoma cells is likely the result of a direct interaction with S100B, which was observed by co-immunoprecipitation experiments. Furthermore, p53 binds regions of the S100B promoter, one of which matches the 20-nucleotide p53-binding consensus DNA sequence perfectly. Therefore, when p53 levels increase, it contributes to its own demise by up-regulating the transcription of S100B as part of a negative feedback loop. This is analogous to what is found for another protein that down-regulates p53, namely hdm2 (human double mutant 2).

The tumor suppressor p53 is a transcription activator that signals for cell cycle arrest and apoptosis and plays a pivotal role in the maintenance and regulation of normal cellular functions (1, 2). Its inactivation affects cell cycle checkpoints, apoptosis, gene amplification, centrosome duplication, and ploidy (2–9). If p53 is inactivated by mutation, as is found in 50% of human cancers, the cell cycle proceeds unregulated, and cell growth proliferates. Likewise, apoptosis pathways are not induced, and proliferating cells transform into cancerous ones (3, 10). On the other hand, if p53 levels are too high, then phenotypes associated with aging, particularly those associated with problems in skin and bone, are observed (11). For these reasons, it is important that p53 protein levels are highly regulated, which is achieved by post-translational modifications and interactions with other proteins inside the cell (5, 12–15). The interactions of p53 with members of the S100 family of calcium-binding proteins (i.e. S100B) are particularly intriguing because they link p53 biology to calcium-mediated signal transduction pathways. There are now >20 members of the S100 family of EF-hand Ca2+-binding proteins, and they are widely distributed in human tissue (16–18). S100 proteins were given this name because they are soluble in 100% saturated ammonium sulfate (19). One member, S100B, is a 21.5-kDa symmetric homodimer that is highly conserved (>95%) among mammals (16, 19). In a manner similar to that of calmodulin, a Ca2+-dependent conformational change is required for S100B to bind target proteins such as p53 (20, 21). Although it is not completely clear how S100B affects cell growth, S100B and several other S100 proteins (i.e. S100A1, mts1) interact with the tumor suppressor protein p53, resulting in significantly reduced p53 levels, and p53-dependent transcription activation of target genes is inhibited (22–24). In primary malignant melanoma cancer cells, we report here that S100B interacts directly with p53 and that inhibiting S100B with siRNA restores the functional p53 protein. These data support the notion that higher than normal levels of S100B, as found in malignant melanoma, are likely contributing to tumor progression by excessive down-regulation of the p53 tumor suppressor protein.

EXPERIMENTAL PROCEDURES
Cells and Cell Treatments—Primary human melanoma C8146A cells were obtained from Dr. Frank L. Meyssens (University of California, Irvine, CA). The cells were grown in F-10 media (Invitrogen) containing 10% fetal bovine serum. The human glioblastoma U118 MG cells were purchased from the American Type Culture Collection (Manassas, VA) and grown in Dulbecco’s modified Eagle’s media (Invitrogen) containing 10% fetal bovine serum. All of the other melanoma cell lines were purchased from the Division of Cancer Treatment and Diagnosis, NCI-Frederick, National Institutes of Health, Frederick, MD, and grown in RPMI 1640 (Invitrogen) containing 10% fetal calf serum. The human large cell lung carcinoma H1299 cells were grown in RPMI 1640 containing 10% fetal bovine serum. The human colorectal carcinoma cell line RKO was provided by Al Fornace, Jr. (NCI, National Institutes of Health, Bethesda, MD), and the cells were grown in RPMI 1640 containing 10% fetal bovine serum. The UV source was a Philips 30-watt germicidal lamp, and the intensities of the UV lamp were determined with a UVX Radiometer (UVP Inc., Upland, CA).

Chloramphenicol Acetyltransferase (CAT) Assays—A fragment of the S100B promoter (nucleotides nt1–3080; GenBank™ numbering) containing seven consensus p53 binding sites (pS100B-1 to...
prS100B-1 to prS100B-7) and three shorter fragments (nt 1435–3080, containing prS100B-2 to prS100B-7, nt 1678–3080, containing prS100B-2 to prS100B-7; and nt 1744–3080, containing prS100B-4 to prS100B-7) of the human S100B promoter (GenBank accession number M59486) were amplified by PCR from the pGBS-4437 plasmid (Linda Van Eldik, Northwestern University, Chicago, IL) containing the full-length human S100B promoter (25). The four PCR products were each inserted into the KpnI and XhoI sites of the pCAT-basic vector (Promega, Madison, WI) and used for transient transfection. The CAT reporter gene construct containing five GADD45 p53-binding sites (p53REX) was provided by Al Fornace Jr. (NCI, National Institutes of Health). The expression vectors used in this study for p53 and GADD153 have been described previously (23). The plasmids were transfected into H1299 cells as non-related vector. (The CAT assay was performed as described previously (23) with the exception that 50 μg (S100B promoter) or 0.5 μg (GADD45 p53 binding site) of cellular extracts were used for the assay. For transcription activation of the S100B promoter by endogenous p53 without or with UV treatment, the CAT assay was performed as above with the exception that no p53 plasmid was co-transfected, and 25 μg (S100B promoter) or 2.5 μg (GADD45 p53 binding site) of cellular extracts were used for the assay. The levels of CAT activity were evaluated by a PhosphorImager (Amersham Biosciences) using the ImageQuant software, and the percentage of relative errors was <15% for each experiment done in quadruplicate.

p53 interference RNA (siRNA)—The 2′-nt double-stranded RNA was synthesized by Ambion (Austin, TX) with standard purification. The sequence (5′-GGAUCUCAUGCCCUUUGU-3′) corresponds to the S100B C-terminal end (nt 216–234) plus a two nt 3′-overhang. This region of S100B was chosen because it is a region of sequence that is homologous with other S100 proteins and, thus, is specific for S100B. Scramble siRNA was bought from Ambion (Sensitive negative control number 1 siRNA, catalog number 4611). Different concentrations of siRNA (2 and 20 nm) were transfected into C8146A melanoma cells using Ambion siPORT lipid transfection agent according to the manufacturer's recommendation. The cells were harvested 48 h later and analyzed by Western Blots.

Western Blots—The Western blot analyses were performed, as described previously (23), on 100 μg of C8146A protein extracts or on 100 μg of U118MG protein extracts. The cells were lysed in radioimmune precipitation assay buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% nonionic detergent P-40, 0.5% sodium deoxycholate, 0.1%, SDS, 1 mM phenylmethylsulfonyl fluoride, 2 μg/ml leupeptin, and 5 μl dithiothreitol). The proteins were run on a 12% polyacrylamide gel, transferred onto nitrocellulose, and reacted with either p53 mouse monoclonal antibody (DO-1, Oncogene Research Products, Boston, MA) at 1:1000 dilution, or Bcl-2 mouse monoclonal antibody (Zymed Laboratories Inc.) at 1:100, Bcl-2 mouse monoclonal antibody (Oncogene Research Products) at 1:100 dilution, MM2 mouse monoclonal antibody (Oncogene Research Products) at 1:100 dilution, or actin mouse monoclonal antibody (Oncogene Research Products) at 1:5000 dilution to control for even protein loading. The blots were then reacted with their respective secondary antibodies conjugated to horseradish peroxidase and reacted with a chemiluminescence substrate (ECL, Amersham Biosciences) as recommended by the manufacturer. Recombinant S100B protein was produced and purified to homogeneity as described previously (23, 26).

Co-immunoprecipitation—The C8146A primary malignant melanoma cells were harvested and washed twice with ice-cold PBS. The cell pellets were lysed for 2 h in lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 2 mM CaCl2, 1 mM phenylmethylsulfonyl fluoride, 2 μg/ml leupeptin and 0.5% Nonidet P-40) and centrifuged at 15,000 rpm. The supernatants (1 mg) were incubated with either p53 antibody (DO-1, cross-linked to agarose beads; Oncogene Research Products) or S100B antibody for 2 h at 4 °C. Myc mouse monoclonal antibody (cross-linked to agarose bead; Oncogene Research Products) and His rabbit polyclonal antibody (Santa Cruz Biotechnology) were used as a negative controls respectively. Protein A-agarose beads (Oncogene Research Products) were then added to the antibody-cell extract mixture, and all reactions were mixed gently overnight at 4 °C. The beads were spun down and washed six times with lysis buffer without detergent and loaded on a 12% polyacrylamide gel for SDS-PAGE. The samples were transferred to a nitrocellulose membrane and incubated with control antibody, S100B antibody, or p53 antibody as described above. A peroxidase-conjugated secondary antibody that does not cross-react with the IgG heavy chain (Jackson ImmunoResearch, West Grove, PA) was used to detect p53 co-immunoprecipitated with the S100B antibody.

Mobility Shift Assay—The electrophoretic mobility shift assay was performed essentially as described previously (27) with the exception that salmon sperm DNA (1 μg) and purified recombinant p53 was used. The baculovirus-expressed p53 was obtained from Proteins Inc. (Baltimore, MD). Baculovirus-expressed p53 was used (0.6 and 3 μg) for binding to the GADD45 and the S100B oligonucleotides, respectively. The probes were purified by reverse phase high pressure liquid chromatography (Vydac C-4) and labeled with T4 polynucleotide kinase (New England Biolabs) as described previously (27). Oligonucleotide sequences from the S100B promoter matching 20 (termed prS100B-3), 17 (termed prS100B-1), and 16 (termed prS100B-2) nucleotides of the p53 binding site (see footnote 2) were sense 5′-GAGTTCTTG CTT TAC AGG AAG-3′ and antisense 3′-tGACTTGTCT-5′. Western Blots (see below).

RESULTS

Wild-type S100B and p53 Protein Levels in Primary Malignant Melanoma Cells—Primary malignant C8146A melanoma cells have relatively high levels of S100B, but wild-type p53 levels are markedly lower in these cancer cells as compared with U118 cells with little or no S100B (Fig. 1A). This observation is consistent with what is found in transient co-transfections of S100B and p53, where levels of the tumor suppressor protein were significantly reduced by the addition of S100B (>100-fold) (23). Using increasing amounts of purified recombinant S100B protein (Fig. 1A; lanes 3–6), we estimated that the levels of S100B in the melanoma C8146A cells are at least 50 times higher than in the U118 cells (Fig. 1A). To verify that the S100B-p53 correlation was specific to C8146A cells or could be found in other melanoma cells, we performed Western blot analyses in five other melanoma cell lines known to have a p53 wild-type genotype (28). The data shown in Fig. 1B indicate that cells having relatively low S100B levels (i.e. LOX-IM VI, UACC-62, and SK-MEL-5) have higher levels of p53, whereas in UACC-2571, C8146A, and Malme 3M cells the S100B levels are relatively high and the p53 levels are lower in all primary melanoma cells. This indicates that the S100B-p53 correlation (i.e. high S100B/lw p53 levels) is consistent in at least six melanoma cell lines.

To determine whether S100B contributes directly to the lowering of p53 levels in the melanoma cancer cells, siRNA corresponding to the C terminus of S100B (siRNA2S100B) was introduced into primary C8146A melanoma cells and compared with results from scrambled siRNA that does not interfere with S100B production (Fig. 2). The addition of the S100B antisense RNA lowered S100B levels by 2.4 ± 0.3-fold and correspondingly, increases in p53 levels (2.5 ± 0.3-fold) were observed.
Likewise, levels of the p21 protein, Bcl-2, and hdm2 (i.e. genes activated by p53) were also upregulated by comparable amounts with the addition of the siRNA of S100B when p53 levels are elevated (Fig. 2). These results with antisense RNA indicate that S100B contributes directly to the down-regulation of functional p53 inside primary malignant melanoma cancer cells and that inhibiting S100B protein production with siRNAS100B restores active p53.

### S100B and wild-type p53 levels in several cancer cell lines

A. Western blots of p53 and S100B in human primary malignant melanoma cells (C8146A; lane 1) and control cells with little or no S100B (glioblastoma U118; lane 2). Actin levels are shown as loading controls. Shown also are blots of purified recombinant S100B used to estimate the amount of S100B in the cancer cells (lanes 3–6); actin levels are shown as loading controls. C. The ratio of p53 to S100B in the six cell lines is shown corresponding to the lane numbers (1–6) from panel B. The bar labeled with the asterisk (*) for the LOX-MM cell line is off-scale and has a p53 to S100B ratio of 11.8 ± 2.8. Together, these data illustrate that skin cancer cells with higher S100B protein levels have diminished levels of wild-type p53.

### S100B Interacts with p53 in Malignant Melanoma

Numerous studies have characterized the high affinity Ca²⁺-dependent interaction between S100B and p53 in vitro (20, 21, 29–31). However, it is critically important to determine whether S100B and p53 interact directly inside cells. To do this, co-immunoprecipitation of the S100B-p53 complex was monitored in C8416 melanoma cells (Fig. 3). The data in Fig. 3 indicate that, in addition to the immunoprecipitation of S100B, the S100B antibody can co-immunoprecipitate p53 (lane 1). The reciprocal immunoprecipitation experiment performed with p53 antibody (lane 2) confirmed the formation of a complex between p53 and S100B in primary malignant melanoma (C8416 cells). As a control, it was shown that nonspecific antibodies of the same isotype could not immunoprecipitate p53 (lane 3) and S100B (lane 4). Therefore, it is likely that a direct interaction between the S100B and p53 proteins contributes to decreased levels of...
Regions of the S100B Promoter Bind p53—When p53 protein levels rise, the transcription of a number of genes involved in the cell cycle and apoptosis are activated. As part of a feedback loop, p53 also up-regulates the transcription of hdmi2 (mdm2 in mice), a protein involved in the ubiquitin-dependent degradation of p53 itself (7, 32, 33). In a situation analogous to that of mice), a protein involved in the ubiquitin-dependent degrad-

in the tumor suppressor, p53, in melanoma with elevated S100B.

The S100B-p53 Interaction in Melanoma

Fig. 4. Mobility shift assays of purified p53 bound to DNA derived from the third intron of GADD45 (lanes 1–3) and a region of the S100B promoter (prS100B-3, 20/20 match) (lanes 4–6). The free probe, the p53-shifted, and the p53 antibody (p53Ab) super-shifted bands are indicated. Baculovirus-expressed p53 was used (0.6 and 3 μg) for binding to the GADD45 and the S100B oligonucleotides, respectively.

The full-length S100B promoter contains 3080; prS100B-3 to prS100B-7), or four consensus p53 binding sites (nt 1679–3080; prS100B-1 to prS100B-7). Together, these data suggest that the regulation of S100B transcription by p53 would occur only after genes with higher affinity p53 sites in their promoters are occupied.

Transcription Is Activated When p53 Binds Regions of the S100B Promoter—The full-length S100B promoter contains seven p53 binding sites (nt 1–3080; prS100B-1 to prS100B-7). Three shorter constructs containing only six sites (nt 1435–3080; prS100B-2 to prS100B-7), five sites (nt 1679–3080; prS100B-3 to prS100B-7), or four consensus p53 binding sites (nt 1744–3080; prS100B-4 to prS100B-7), respectively, were also cloned into a CAT reporter gene construct to determine whether p53 affects S100B transcription. Transient transfe-

Fig. 5. Transcription activation of the S100B promoter in cells (H11299) in which the p53 gene is eliminated (p53−/−). A, lanes 1–6, controls for the S100B DNA constructs/transfections in the absence of p53. Lane 7, control transfection of p53 in the absence of an S100B promoter construct. Lane 8, co-transfection of p53 and the full-length S100B promoter. Transcription activation by p53 is measured by CAT activity for the full-length S100B promoter, S100B 7p53, that includes all seven p53 binding sites (nt 1–3080; prS100B-1 to prS100B-7). Lane 9, p53 transcription activation of a promoter construct of S100B with six of seven of the p53 binding sites, S100B 6p53 (nt 1435–3080; prS100B-2 to prS100B-7). Lane 10, p53 transcription activation of an S100B promoter construct that has five of seven of the p53-binding sites (nt 1679–3080; prS100B-3 to prS100B-7); this construct still retains the prS100B-3 sequence that has a 20 of the 20 nucleotides matching the p53 consensus sequence. Lane 11, p53 transcrip-

The S100B-p53 Interaction in Melanoma

Fig. 4. Mobility shift assays of purified p53 bound to DNA derived from the third intron of GADD45 (lanes 1–3) and a region of the S100B promoter (prS100B-3, 20/20 match) (lanes 4–6). The free probe, the p53-shifted, and the p53 antibody (p53Ab) super-shifted bands are indicated. Baculovirus-expressed p53 was used (0.6 and 3 μg) for binding to the GADD45 and the S100B oligonucleotides, respectively.

The full-length S100B promoter contains 3080; prS100B-3 to prS100B-7), or four consensus p53 binding sites (nt 1679–3080; prS100B-1 to prS100B-7). Together, these data suggest that the regulation of S100B transcription by p53 would occur only after genes with higher affinity p53 sites in their promoters are occupied.

Transcription Is Activated When p53 Binds Regions of the S100B Promoter—The full-length S100B promoter contains seven p53 binding sites (nt 1–3080; prS100B-1 to prS100B-7). Three shorter constructs containing only six sites (nt 1435–3080; prS100B-2 to prS100B-7), five sites (nt 1679–3080; prS100B-3 to prS100B-7), or four consensus p53 binding sites (nt 1744–3080; prS100B-4 to prS100B-7), respectively, were also cloned into a CAT reporter gene construct to determine whether p53 affects S100B transcription. Transient transfe-

similar data were obtained with the two other p53 consensus sites in the S100B promoter (nt 149–169, prS100B-1; nt 1455–1478, prS100B-2); however, these sites had lower affinity for p53 than did the 20/20 sequence, prS100B-3 (data not shown). Together, these data suggest that the regulation of S100B transcription by p53 would occur only after genes with higher affinity p53 sites in their promoters are occupied.

Transcription Is Activated When p53 Binds Regions of the S100B Promoter—The full-length S100B promoter contains seven p53 binding sites (nt 1–3080; prS100B-1 to prS100B-7). Three shorter constructs containing only six sites (nt 1435–3080; prS100B-2 to prS100B-7), five sites (nt 1679–3080; prS100B-3 to prS100B-7), or four consensus p53 binding sites (nt 1744–3080; prS100B-4 to prS100B-7), respectively, were also cloned into a CAT reporter gene construct to determine whether p53 affects S100B transcription. Transient transfe-

similar data were obtained with the two other p53 consensus sites in the S100B promoter (nt 149–169, prS100B-1; nt 1455–1478, prS100B-2); however, these sites had lower affinity for p53 than did the 20/20 sequence, prS100B-3 (data not shown). Together, these data suggest that the regulation of S100B transcription by p53 would occur only after genes with higher affinity p53 sites in their promoters are occupied.

Transcription Is Activated When p53 Binds Regions of the S100B Promoter—The full-length S100B promoter contains seven p53 binding sites (nt 1–3080; prS100B-1 to prS100B-7). Three shorter constructs containing only six sites (nt 1435–3080; prS100B-2 to prS100B-7), five sites (nt 1679–3080; prS100B-3 to prS100B-7), or four consensus p53 binding sites (nt 1744–3080; prS100B-4 to prS100B-7), respectively, were also cloned into a CAT reporter gene construct to determine whether p53 affects S100B transcription. Transient transfe-

similar data were obtained with the two other p53 consensus sites in the S100B promoter (nt 149–169, prS100B-1; nt 1455–1478, prS100B-2); however, these sites had lower affinity for p53 than did the 20/20 sequence, prS100B-3 (data not shown). Together, these data suggest that the regulation of S100B transcription by p53 would occur only after genes with higher affinity p53 sites in their promoters are occupied.

Transcription Is Activated When p53 Binds Regions of the S100B Promoter—The full-length S100B promoter contains seven p53 binding sites (nt 1–3080; prS100B-1 to prS100B-7). Three shorter constructs containing only six sites (nt 1435–3080; prS100B-2 to prS100B-7), five sites (nt 1679–3080; prS100B-3 to prS100B-7), or four consensus p53 binding sites (nt 1744–3080; prS100B-4 to prS100B-7), respectively, were also cloned into a CAT reporter gene construct to determine whether p53 affects S100B transcription. Transient transfe-

similar data were obtained with the two other p53 consensus sites in the S100B promoter (nt 149–169, prS100B-1; nt 1455–1478, prS100B-2); however, these sites had lower affinity for p53 than did the 20/20 sequence, prS100B-3 (data not shown). Together, these data suggest that the regulation of S100B transcription by p53 would occur only after genes with higher affinity p53 sites in their promoters are occupied.

Transcription Is Activated When p53 Binds Regions of the S100B Promoter—The full-length S100B promoter contains seven p53 binding sites (nt 1–3080; prS100B-1 to prS100B-7). Three shorter constructs containing only six sites (nt 1435–3080; prS100B-2 to prS100B-7), five sites (nt 1679–3080; prS100B-3 to prS100B-7), or four consensus p53 binding sites (nt 1744–3080; prS100B-4 to prS100B-7), respectively, were also cloned into a CAT reporter gene construct to determine whether p53 affects S100B transcription. Transient transfe-
The S100B-p53 Interaction in Melanoma

Fig. 6. Transcription activation of the S100B promoter by endogenous wild-type tumor suppressor protein p53 (in RKO cells) without or with UV treatment. A, Western blots of p53 and S100B in the human colorectal carcinoma cell line RKO before and after UV treatment. Actin was used as loading control. B, lanes 1–7, controls that are not treated with UV radiation include the following: RKO cell without any transfected construct (lane 1); control in the absence of the S100B promoter construct (lane 2); transcription activation by endogenous p53 as measured by CAT activity for the full-length S100B promoter, S100B/5p53, that includes all seven p53 binding sites (nt 1–3080; prS100B-1 to prS100B-7) (lane 3); p53 transcription activation by an S100B promoter construct (nt 1744–3080; prS100B-4 to prS100B-7) containing four of the seven consensus p53 binding sites (nt 1679–1744) (lane 4); and positive control showing the p53 transcription activation of genes involved in apoptosis (i.e., Bax, etc.) and cell cycle-dependent growth arrest (i.e., p21 etc.). As part of a feedback control mechanism, p53 also up-regulates the transcription of genes involved in its own inactivation (i.e., hdm2 and S100B). As part of a cell growth response (Ca2⁺), the Ca2⁺-dependent interaction between S100B and p53 induces a conformational change in p53 and tetramer dissociation of the tumor suppressor (29), which likely contributes to its degradation (i.e., perhaps involving hdm2/ubiquitin- and/or protease-dependent pathways). Thus, down-regulation of p53 by S100B and hdm2 ultimately facilitates cell growth. ATM, ataxia telangiectasia mutated kinase; ATR, ATM- and Rad-3-related kinase; p14Arf, alternative reading frame (human).

FIG. 7. Scheme for the down-regulation of wild-type p53. p53 is activated upon DNA damage or under stress and up-regulates the transcription of genes involved in apoptosis (i.e., Bax, etc.) and cell cycle-dependent growth arrest (i.e., p21 etc.). As part of a feedback control mechanism, p53 also up-regulates the transcription of genes involved in its own inactivation (i.e., hdm2 and S100B). As part of a cell growth response (Ca2⁺), the Ca2⁺-dependent interaction between S100B and p53 induces a conformational change in p53 and tetramer dissociation of the tumor suppressor (29), which likely contributes to its degradation (i.e., perhaps involving hdm2/ubiquitin- and/or protease-dependent pathways). Thus, down-regulation of p53 by S100B and hdm2 ultimately facilitates cell growth. ATM, ataxia telangiectasia mutated kinase; ATR, ATM- and Rad-3-related kinase; p14Arf, alternative reading frame (human).
The S100B-p53 Interaction in Melanoma

high (as compared with the p53 levels needed to activate other genes such as GADD45).

DISCUSSION

In its active form, each subunit of tetrameric p53 binds Zn\(^{2+}\) and contains a sandwich of two antiparallel \(\beta\)-sheets that serve as a scaffold for a loop-sheet-helix DNA binding domain (33). When cells are under stress (i.e. UV radiation, DNA damage, etc.), elevated levels of p53 bind specific DNA sequences and activate the transcription of downstream targets, including a cyclin-dependent kinase inhibitor (p21\(^{WAF/CIP1}\)), cell cycle control proteins (cyclin G, GADD45), genes involved in apoptosis (i.e. Bcl2), and, eventually, proteins such as S100B and hdm2, which, in turn, negatively regulate p53 protein levels inside the cell via feedback control (1, 2, 32). In Fig. 7, a scheme is presented for how p53 is down-regulated by hdm2 and S100B as a part of feedback control to ensure that p53 levels do not get elevated to excessive levels.

For S100B, the affinity of p53 for its promoter regions are relatively low (Figs. 4–6), which suggests that regulation of S100B by p53 would occur only after higher affinity promoter sites are occupied (i.e. for GADD45). This idea is further supported by p53 transcription activation assays performed with shorter constructs of the S100B promoter (Figs. 5 and 6), which indicates that additional negative regulatory elements exist in the full-length promoter that reduce p53-dependent transcription activation of the S100B gene. Specifically, at the levels of the p53 protein necessary to activate the transcription of S100B, numerous other genes (i.e. GADD45, p21, etc.) will have already been transcribed. This, of course, is a scenario that one might expect for the regulation of a gene such as S100B, which is involved in a feedback loop that ultimately leads to lowering the levels of functional p53.

Interestingly, p53 is also known to up-regulate the transcription of another S100 protein, S100A2 (36) by binding the p53-binding consensus sequences found in its promoter. Furthermore, several other S100 proteins (i.e. S100A1, S100A4, and S100A9) have consensus p53 binding sequences in their respective promoters, so it is likely that several other S100 proteins are also regulated by p53. However, more work needs to be done before general conclusions can be made about the functional significance of regulatory pathways involving p53 and other S100 family members.

The lowering of p53 protein levels inside cells by S100B that was observed here (Fig. 2) and previously (23) is most likely related to the ability of S100B to bind directly to p53 (Fig. 3), dissociate the p53 tetramer (29), and/or cause conformational changes in the extreme C terminus and tetramerization domains of the tumor suppressor (30). Such effects by S100B may work synergistically with the hdm2 protein/pathways, which are involved in the ubiquitin-dependent degradation of p53 (37), although this concept needs to be rigorously established.

Nonetheless, an important distinction between these two negative regulatory proteins (hdm2 versus S100B) is that the S100B interaction with the C terminus of p53 is Ca\(^{2+}\)-dependent (21) and links p53 biology to calcium-mediated signaling pathways and extracellular growth responses, whereas, hdm2 binds the N terminus of p53 in a calcium-independent manner and is regulated by other proteins (i.e. p14\(^{ARF}\)) as signaling pathways and the phosphorylation state of p53 (33, 37, 38) (Fig. 7).

It is important to understand how cancer cells, such as those in malignant melanoma, can proliferate even though they have wild-type p53. One possible explanation for this paradigm is that elevated levels of the proteins that negatively regulate p53, such as S100B, may be a culprit. Specifically, the overall effect of elevated S100B levels on wild-type p53 could mimic cellular aberrations such as gene amplification and mutations that are encountered with non-functional mutants of p53. Specifically, several melanomas have wild-type p53 and higher than normal levels of S100B, and the prognosis for patients such as these is generally poorer than for those with lower S100B levels (39–41). For primary skin cancer cells, we show that there is a direct interaction between p53 and S100B and that functional wild-type p53 levels can be restored when S100B levels are lowered by siRNA (Fig. 2). This result directly implicates S100B in the down-regulation of wild-type p53 and is consistent with the large decreases in p53 protein levels observed previously in transient co-transfections of p53 and S100B (23). With these results in mind, perhaps a small molecule inhibitor that binds S100B, blocks the S100B-p53 interaction, and restores wild-type p53 levels (i.e. an siRNA\(^{S100B}\) mimic) could be useful in therapeutic strategies for the treatment of cancers with elevated S100B, such as some forms of malignant melanoma and glioma.

REFERENCES

1. Levine, A. J., Momand, J., and Finlay, C. A. (1991) Nature 351, 453–456
2. Levine, A. J. (1997) Cell 88, 323–331
3. Woods, D. R., and Vousden, K. H. (2001) Exp. Cell Res. 264, 56–66
4. Burns, T. F., and El-Deiry, W. S. (1990) J. Cell. Physiol. 141, 231–239
5. Appella, E., and Anderson, C. W. (2001) Eur. J. Biochem. 268, 2764–2772
6. Arrowsmith, C. H. (1999) Cell Death Differ. 6, 1169–1173
7. Prives, C., and Hall, P. A. (1999) J. Pathol. 187, 112–126
8. Vousden, K. H. (2000) Cell 103, 691–694
9. Ryan, K. M., Phillips, A. C., and Vousden, K. H. (2001) Curr. Opin. Cell Biol. 13, 322–337
10. Agarwal, M. L., Taylor, W. R., Chernov, M. V., Chernova, O. B., and Stark, G. R. (1998) J. Biol. Chem. 273, 1–4
11. Tyner, S. D., Venkatasubramani, C., Choi, J., Jones, S., Ghebranious, N., Igelmann, H., Lu, X., Soron, G., Cooper, B., Brayton, C., Lee, P. S., Thompson, T., Karsteny, G., Bradley, A., and Donehower, L. A. (2002) Nature 416, 45–53
12. Minamoto, T., Buschmann, T., Habelhah, E., Matsuevich, E., Tahara, H., Boerresen-Dale, A. L., Harris, C., Sidransky, D., and Ronai, Z. (2001) Oncogene 20, 3341–3347
13. Jayaraman, L., and Prives, C. (1999) Cell Mol. Life Sci. 55, 76–87
14. Jimenez, G. S., Khan, S. H., Stommel, J. M., and Wahl, G. M. (1999) Oncogene 18, 7656–7665
15. Meek, D. W. (1997) Pathol. Biol. 45, 804–814
16. Zinner, D. B., Corwal, E. H., Landar, A., and Song, W. (1995) Brain Res. Bull. 37, 417–429
17. Donato, R. (2001) Int. J. Biochem. Cell Biol. 33, 637–668
18. Heinemann, C. W., Fritz, G., and Schafer, B. W. (2002) Front. Biosci. 7, 1356–1368
19. Moore, B. (1965) Biochem. Biophys. Res. Comm. 19, 739–744
20. Rustandi, R. R., Baldissieri, D. M., and Weber, D. J. (2000) Nat. Struct. Biol. 7, 570–574
21. Rustandi, R. R., Drobh, A. C., Baldissieri, D. M., Wilder, P. T., and Weber, D. J. (1999) Biochemistry 38, 1951–1960
22. Grigorjan, M., Andresen, S., Tulchinsky, E., Krajewska, M., Carlborg, C., Krause, C. Cohn, M., Ambartsumian, N., Christensen, A., Selivanova, G., and Lukandin, E. (2001) J. Biol. Chem. 276, 22699–22708
23. Lin, J., Blake, M., Tang, C., Zimmer, D., Rustandi, R. R., Weber, D. J., and Carrier, F. (2001) J. Biol. Chem. 276, 35307–35314
24. Carrier, F., Blake, M., Zimmer, D., Rustandi, R. R., and Weber, D. J. (1999) Proc. Am. Assoc. Cancer Res. 40, 102
25. Castets, G., Griffith, W. S., Marks, A., and Van Eldick, L. J. (1997) Brain Res. 766, 208–216
26. Amburgey, J. C., Aihlgaard, F., Storch, M. R., Shah, S., Hilt, D. C., and Weber, D. J. (1995) J. Biol. Chem. 270, 171–179
27. Carrier, F., Bae, I., Smith, M. L., Ayers, D. M., and Fornace, A. J., Jr. (1996) 
Mut. Res. 352, 79–86
28. O'Connor, P. M., Jackman, J., Bae, I., Myers, T. G., Fan, S., Mutoh, M., 
Scudiero, D. A., Monks, A., Sausville, E. A., Weinstein, J. N., Friend, S., 
Fornace, A. J., Jr., and Kohn, K. (1997) Cancer Res. 57, 4285–4300
29. Baudier, J., Delphin, C., Grunwald, D., Khochbin, S., and Lawrence, J. J. 
(1992) Proc. Natl. Acad. Sci. U. S. A. 89, 11627–11631
30. Rustandi, R. R., Baldissieri, D. M., Druhit, A. C., and Weber, D. J. (1999) 
Protein Sci. 8, 1743–1751
31. Weber, D. J., Rustandi, R. R., Carrier, F., and Zimmer, D. B. (2000) in The 
Molecular Basis of Calcium Action in Biology and Medicine (Pochet, R., ed) 
pp. 521–539, Kluwer Academic Publishers, Dordrecht, The Netherlands
32. Freedman, D. A., Wu, L., and Levine, A. J. (1999) Cell. Mol. Life Sci. 55, 
96–107
33. Momand, J., Wu, H. H., and Dasgupta, G. (2000) Gene 242, 15–29
34. Kastan, M. B., Zhan, Q., el-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., 
Plunkett, B. S., Vogelstein, B., and Fornace, A. J., Jr. (1992) Cell 71, 
587–597
35. Cho, Y., Gorina, S., Jeffrey, P. D., and Pavletich, N. P. (1994) Science 265, 
346–355
36. Tan, M., Heizmann, C. W., Guan, K., Schafer, B. W., and Sun, Y. (1999) FEBS 
Lett. 445, 265–268
37. Ashcroft, M., and Vousden, K. H. (1999) Oncogene 18, 7637–7643
38. Prives, C. (1998) Cell 95, 5–8
39. Cochran, A. J., Lu, H. F., Li, P. X., Saxton, R., and Wen, D. R. (1993) Melanoma 
Res. 3, 325–330
40. Boni, R., Heizman, C. W., Dogunglu, A., Ilg, E. C., Schafer, B. W., Dummer, R., 
and Burg, G. (1997) J. Cutan. Pathol. 24, 76–80
41. Marks, A., Petsche, D., O’Hanlon, D., Kwong, P. C., Stead, R., Dunn, R., 
Baumal, R., and Liao, S. K. (1990) Exp. Cell Res. 187, 59–64
Inhibiting S100B Restores p53 Levels in Primary Malignant Melanoma Cancer Cells
Jing Lin, Qingyuan Yang, Zhe Yan, Joseph Markowitz, Paul T. Wilder, France Carrier
and David J. Weber

J. Biol. Chem. 2004, 279:34071-34077.
doi: 10.1074/jbc.M405419200 originally published online June 3, 2004

Access the most updated version of this article at doi: 10.1074/jbc.M405419200

Alerts:
• When this article is cited
• When a correction for this article is posted

Click here to choose from all of JBC’s e-mail alerts

This article cites 40 references, 6 of which can be accessed free at
http://www.jbc.org/content/279/32/34071.full.html#ref-list-1